Product prices include realized gains and losses on risk management activities and financial instrument contracts. This news release contains forward-looking information and statements (collectively, ...

The market shrugged off Tourmaline Oil Corp.'s (TSE:TOU) solid earnings report. Our analysis showed that there are some concerning factors in the earnings that investors may be cautious of. AI is ...

CRYSTALS are sources of power and may help provide a sense of balance and relief to those who believe. The Tourmaline is a gemstone that comes with a wide variety of healing properties, as well as ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Tourmaline has an expansion plan and expects to increase its production by 36.40% from 2024 to 2029. TOU:CA expects to pay CA$750 million over the next years in base dividends. At that level, ...

BERLIN (Reuters) - Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on ...

First quarter 2026 average production was 666,089 boepd, within the guidance range of 660,000 - 670,000 boepd. Full year 2026 average production of 620,000 to 640,000 boepd is anticipated, which ...

Second quarter 2022 cash flow (1)(2) ("CF") was a record $1.35 billion ($3.95 per diluted share (3)), a 137% increase over second quarter 2021 cash flow. Net debt (4) at June 30, 2022, was $430.0 ...

Novartis NOVN1.01%increase; up pointing triangle agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy ...